The last multicentered analysis of extracorporeal membrane oxygenation in pediatric acute respiratory failure was completed in 1993. We reviewed recent international data to evaluate survival and predictors of mortality.
A cute respiratory failure (ARF) is a common condition treated in pediatric intensive care units and remains an important cause of morbidity and mortality. Strategies to improve the treatment of severe disease include small tidal volume ventilation (1) , high-frequency oscillatory ventilation (HFOV) (2), surfactant therapy (3, 4) , inhaled nitric oxide (5) , prone positioning (6 -9) , kinetic therapy (10) , and corticosteroid administration (11) . Despite these efforts, the reported mortality rates of ARF due to acute lung injury or acute respiratory distress syndrome (ARDS) in pediatric patients remain high (18% to 35%) (12) (13) (14) .
Extracorporeal membrane oxygenation (ECMO) has been used for nearly 30 yrs as "rescue" therapy for pediatric ARF; however, optimal use relies on appropriate patient selection. The ideal candidate has high predicted mortality yet potentially reversible lung injury. The currently available data used to guide patient selection rely primarily on multicentered reports encompassing data analyzed before 1994 (15) (16) (17) (18) . These studies demonstrated survival approximating 50% overall, with improved survival associated with younger age, lower pre-ECMO ventilator pressures, better oxygenation, and shorter duration of mechanical ventilation before ECMO support.
The need to institute ECMO before the development of ventilator-induced lung injury was demonstrated by several early studies in pediatric (17, 19) and adult (20) patients. Due to a lower survival for patients with longer pre-ECMO ventilation times, accepted pediatric criteria for patient selection typically include mechanical ventilation of Ͻ7-10 days (21, 22) .
The Extracorporeal Life Support Organization (ELSO) provides education, support, and certification for ECMO centers worldwide and maintains a registry of treated patients. We used this to identify subjects and analyze patient characteristics associated with death for infants and children supported by ECMO for ARF from 1993 to 2007. We hypothesized that survival in this time period would be unchanged but that patients would be more medically complex and preexisting conditions would be associated with mortality (23, 24) .
MATERIALS AND METHODS
ELSO collects case data from Ͼ115 ECMO centers worldwide through voluntary reporting. Data include a primary indication for ECMO therapy designated as "pulmonary," "cardiac," or "E-CPR" and detailed patient demographics and ECMO support data. The ELSO registry (Ann Arbor, MI) was queried for all pediatric patients Յ18 yrs of age treated from January 1, 1993 to December 31, 2007 for a primary pulmonary indication (n ϭ 3717). Exclusion criteria included age of Ͻ30 days (n ϭ 432) and lack of a valid respiratory diagnosis verified by the ICD-9 (International Classification of Diseases, version 9) coding (25) (n ϭ 13). For patients with multiple ECMO runs (n ϭ 59), only the first was included.
Primary diagnosis ICD-9 codes as well as secondary diagnoses and current procedural terminology codes were examined independently by two investigators (LAZ and SLB), who assigned a primary respiratory diagnosis. Any disagreements (n ϭ 68) were resolved by a third investigator (KDS). In a similar fashion, diagnosis codes were also used to determine 11 comorbid conditions.
For statistical analysis, ECMO support was classified as venovenous (VV) or venoarterial (VA). Children converted to a different mode (VV-VA or VA-VV) were classified under their final mode for the multivariable model.
The primary outcome was death before hospital discharge. Categorical variables were analyzed by using Fisher's exact test or Pearson's chi-square test while continuous variables were analyzed by using a Mann-Whitney U test or the Kruskal-Wallis test when comparing more than two groups. Data are reported as frequency (n) with proportion (%), or median values with interquartile range (25th to 75th percentiles) unless specified otherwise. All statistical analysis was performed by using SPSS 16.0 for Macintosh (IBM, Chicago, IL). Significance was determined as p Ͻ .05.
A multivariable logistic regression model was developed to evaluate patient demographics, pre-ECMO clinical factors, and initial ECMO features associated with death. Variables that were statistically associated with death in a bivariate analysis were considered as candidate variables in the multivariable model by using a forward step-wise selection procedure. Inclusion cutoff for the model was set as a probability value of Յ.05 and exclusion as .15. The reference group for primary diagnostic categories was created by using all pul-monary diagnosis groups with mortality equal to the overall mean and included the following: bacterial pneumonia, viral pneumonia, influenza, and ARDS related to trauma or surgery (n ϭ 1060). Hematopoietic stem cell transplant patients were excluded due to small sample size and concerns of over fitting the model.
The variables not meeting linearity assumptions were divided into categories. For example, last blood pH before ECMO was tricotimized into pH Ͻ7.19, 7.2-7.29, and Ͼ7. 29 . Cutoff values were chosen based on the lower 25th quartile and median pH among the entire cohort. For alveolar-arterial gradient calculations, the atmospheric pressure was estimated to be 760 mm Hg, and an R quotient of .8 was used. Adjusted odds ratios with 95% confidence intervals were reported. The cases with missing data were excluded. The Nagelkerke statistic was reported as a measure of variability explained by the model.
This study used only deidentified data and was compliant with the exempt categories of research defined by our university's institutional review board.
RESULTS

Patient Demographics
During the 15-yr period (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) , 3213 pediatric patients met study criteria. Patient demographics are reported in Table 1 . Survival did not differ by gender. Survivors had a significantly lower median weight (9 [IQR 4 -17] kg vs. 9.9 [IQR 4.3-23] kg) but similar median age compared with those who died. However, children ages 10 -18 yrs had a significantly lower survival (50%) than infants, toddlers, and children (57%, 61%, and 55%, respectively).
Historical Trends
The use of ECMO for respiratory failure remained relatively stable since 1993 with no significant change in survival before hospital discharge ( Fig. 1 ). In 1993, 19% of patients had a reported comorbid condition, which increased to 47% by 2007. Although overall survival did not change, the survival among children without any underlying comorbid condition increased significantly from 57% in 1993 to 72% in 2007.
Primary Diagnosis and Comorbid Conditions
Primary respiratory diagnoses are reported in Table 2 . Pneumonia related to Bacterial pneumonia, other viral pneumonia, influenza, and ARDS related to trauma or surgery had similar survivals ranging from 56% to 59% (n ϭ 1,060). Diagnoses with higher survival included status asthmaticus (83%), aspiration pneumonia (71%), and respiratory syncytial virus pneumonia (70%). The lowest survival was associated with fungal pneumonia (23%), pertussis (39%), and ARDS related to sepsis (40%). Thirty-four percent of patients had at least one underlying comorbid condition. Acute or chronic renal failure was the most common, with a hospital survival of only 33%. The presence of congenital heart disease or chronic lung disease was not significantly associated with survival. Only 16% of patients with underlying liver failure survived. Patients with an immunodeficiency also had low survival. There were 22 patients with a hematopoietic stem cell transplant, and only one survived to hospital discharge. This was a 15-month-old boy treated in 2004 with an autoimmune disorder. Eighty-eight patients (3%) had a cardiac arrest before ECMO support, and 38% survived.
Pre-ECMO Ventilation
Patients ventilated Յ14 days before ECMO had similar survivals (56% to 61%), but those supported with mechanical ventilation longer had significantly lower survival (38%) survival (56% to 61%), but those supported with mechanical ventilation longer had significantly lower survival (38%) (Fig. 2 ). More patients were treated with conventional ventilation (49%) than with HFOV (38%) before ECMO. Those treated with HFOV had a longer median length of ventilation before ECMO (4.6 days [IQR 2-8.2]) compared with conventional ventilation (3 days [IQR 1-7]); however, survival did not differ based on the mode of pre-ECMO ventilation ( Table 3 ). The use of HFOV before ECMO did not change over the past 15 yrs among patients supported by ECMO (data not shown).
ECMO Delivery Features
Sixty-four percent of patients were treated with VA ECMO and 34% with VV ECMO. There was a trend from 1993 to 2007 for increased use of VV ECMO (35% to 46%), as well as use of double-lumen VV catheters (1% to 19%). VV vs. VA ECMO was associated with improved survival. Hospital survival was 70% for patients supported by a double-lumen VV catheter. Survival with two-catheter VV support was 66%, whereas survival with VA support was significantly lower at 51%. There were 211 patients transitioned from VV to VA ECMO with a survival of 49%, similar to patients initially treated with VA ECMO (p ϭ .488).
Ventilator Settings and Blood Gas Values
The median duration of mechanical ventilation before ECMO was 3.5 days, which differed significantly for survivors (3.1 days [IQR 1.1-7]) and nonsurvivors (4 days [IQR 1.3-8.5]) ( Table 4 ). Ventilator support settings used immediately before the initiation of ECMO differed statistically between survivors and nonsurvivors; however, the differences did not appear clinically important. For instance, the median positive end-expiratory pressure for both groups was 10 cm of water pressure; however, the upper range was greater in those who died. Likewise, blood gas measurements prior to the initiation of ECMO and measures of oxygenation were significantly worse in those who died with a median oxygenation index of 48 compared with 42 in those who survived. Pre-ECMO pH was also statistically greater with a median pH of 7.31 (IQR 7.2-7.41) among those who survived compared with 7.27 (IQR 7.16 -7.38) among those who died. Both survivors and nonsurvivors had a median pre-ECMO pH that steadily worsened over the study years. There was a corresponding trend for increased PaCO 2 but no change in HCO 3 during the study years. Comparison of ventilation parameters and blood gas values after 24 hrs of ECMO support did not reveal important differences by survival status (data not shown).
Predictors of Mortality
A multivariable logistic regression model was developed to evaluate patient demographics and pre-ECMO support characteristics independently associated with mortality (Table 5 ). Compared with the reference group (bacterial pneumonia, other viral pneumonia, influenza, and ARDS related to trauma or surgery), patients with a diagnosis of pertussis, ARDS related to sepsis, or fungal pneumonia had significantly increased odds of mortality, whereas patients with status asthmaticus, aspiration, or respiratory syncytial virus had decreased odds of death. The presence of liver failure, can- 
DISCUSSION
The decision to offer ECMO as a rescue therapy for pediatric ARF is clinically difficult because the data available to make an accurate risk/benefit assessment are limited and may not reflect current practice. Our goal was to conduct a detailed analysis of currently available international data to determine survival rates and identify factors associated with mortality. Our main findings include the following: 1) survival rates are unchanged over the past 15 yrs despite ECMO support of patients with increased comorbidities; 2) patients receiving mechanical ventilation from 1 to 2 wks before the initiation of ECMO have similar survival compared with patients ventilated for shorter periods of time; 3) the duration of pre-ECMO ventilation longer than 2 wks is associated with increased mortality; and 4) other important predictors of mortality include a diagnosis of pertussis, ARDS related to sepsis, or fungal pneumonia, the presence of multisystem organ failure or immunodeficiency, and older patient age.
Survival for patients without comorbidities steadily improved; however, the number of patients with a comorbid condition also increased. Pre-ECMO acidosis, an independent predictor of mortality, steadily worsened over the study period with a corresponding increase in PaCO 2 , consistent with worsening respiratory derangements among children rescued with ECMO. Thus the unchanged survival rate likely reflects an increasingly complex patient population, perhaps due to improvements in conventional therapies. Any survival benefits from improved ECMO technology and expanded experience are therefore likely countered by the increased patient complexity.
The most common respiratory diagnoses were related to viral pneumonias. Compared with recent studies on the incidence and etiologies of ARDS by Flori et al (12) and Zimmerman et al (14) , our study demonstrates a proportionately higher rate of pneumonia and a lower rate of sepsis and submersion injury. It is likely that children supported by ECMO for respiratory failure differ from those with ARDS. Patients with asthma, aspiration pneumonia, and respiratory syncytial virus pneumonia had higher survival compared with other children treated with ECMO for respiratory failure. This may be due to an inherent reversibility of the disease process or due to the absence of associated multiorgan failure. Finally, patients with fungal pneumonia, pertussis, and ARDS due to sepsis have quite poor survival and clinical courses often complicated by multiorgan failure.
As expected, patients with a comorbid condition before ECMO had increased mortality (26, 27) . Patients with either renal failure or liver dysfunction had particularly high mortality, consistent with past reports (28, 29) . Like Gupta et al (24) and Gow et al (30) , we found high mortality for those with an immunocompromised condition and particularly among children with a hematopoietic stem cell transplant. Surprisingly, the presence of congenital heart disease or chronic lung disease had no apparent effect on mortality. In contrast, several studies focusing on ECMO for cardiac support have shown higher mortality before hospital discharge (31) (32) (33) . In a study focused on the use of HFOV, Arnold et al (2) reported that patients with congenital heart disease or chronic lung disease had greater risk of death. Our study supports ECMO support for children with severe respiratory failure complicated by congenital heart disease or chronic lung disease.
A critical ECMO patient selection criterion is reversible lung injury. Unfortunately, this assessment is imprecise, but ventilator-associated lung injury clearly limits survival in severe respiratory failure (1), and mechanical ventilation for Ͼ7 days has been frequently cited as either a contraindication to ECMO or an argument for earlier institution of ECMO support (15, 21, 34) . The "window" to institute ECMO with contemporary ventilator strategies appears to be longer than previously reported. It was not until 2 wks of mechanical ventilation pre-ECMO that mortality increased significantly. Ventilation mode (conventional or high frequency) was not significantly associated with mortality, consistent with previous studies (35) .
There was a steady increase in VV ECMO compared with VA ECMO with a marked increase in double-lumen VV cannulation. Patients treated with VV ECMO had improved survival likely due in part to patient selection because VV ECMO offers no direct cardiac support and more-critically-ill patients are often placed on VA ECMO. This is further confounded by patient age, as double-lumen cannulation has only been available to support children up to 20 kg. As multilumen catheters become more readily available for larger patients, there may be a further increase in use. Previous studies did not find a survival benefit for VV vs. VA ECMO (36) . Importantly, patients initially treated with VV ECMO but later converted to VA ECMO had similar survival to those supported solely with VA ECMO, suggesting that a trial of VV ECMO for patients with some cardiovascular dysfunction support is a reasonable option. Clearly, the theoretical benefits including decreased risk of stroke make VV the preferred method for ECMO delivery when possible (37) .
Patient demographics in this study are similar to prior reports (15) (16) (17) (18) . Survival was lower among older patients (15, 18, 38) ; however, the effect of age was less than previously reported with similar survival for infants, toddlers, and young children. Mortality in the 10-to 18-yr age group is comparable to recently reports of adult patients supported with ECMO (39) .
Our study has several limitations. As a retrospective study, it is limited by the detail and completeness of the collected data. The ELSO registry does not contain severity-of-illness information. The demonstrated increase in comorbidities over time may be related in part to progressive improvement in data capture over the 15-yr time span; however, ECMO providers have noted increased patient complexity (23, 24) . Some pre-ECMO information had excessive missing data, which may have prevented the resolution of important associations with mortality.
ELSO does not release information related to center; therefore, center volume/ expertise could not be assessed. Finally, the only outcome collected is hospital mortality, and thus information regarding long-term pulmonary status or cognitive outcome is lacking. However, randomized studies of ECMO in neonates (40) and adults (41) treated for respiratory failure found improved functional status compared with conventional therapies. Long-term survival after ECMO is not known but may be declining as increasing numbers of children with more complex conditions are being supported.
CONCLUSIONS
Over the past 15 yrs, children treated with ECMO for ARF are more medically complex. Patients with ARDS related to sepsis, liver failure, renal failure, and immunodeficiencies have higher mortality, as do patients with a pre-ECMO severe acidosis. Pre-ECMO ventilation up to 2 wks should not be a restriction for ECMO treatment. We hope that the findings presented in this paper aid clinicians in selecting an appropriate patient population for rescue therapy with ECMO.
